Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;51(7):1233-40.
doi: 10.3109/10428194.2010.486877.

Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia

Tait D Shanafelt  1 , Kari G Rabe, Neil E Kay, Clive S Zent, Timothy G Call, Susan L Slager, Deborah A Bowen, Susan M Schwager, Grzegorz S Nowakowski
Affiliations

Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia

Tait D Shanafelt et al. Leuk Lymphoma. 2010 Jul.

Abstract

Statins and non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed medications. In vitro studies suggest that statins and NSAIDs may have potential as anticancer therapies in low-grade non-Hodgkin lymphomas including chronic lymphocytic leukemia (CLL), and a recent observational study found statin use was associated with improved event free survival in patients with follicular lymphoma. Other studies have suggested that statins reduce the efficacy of rituximab by inhibiting binding to CD20. We therefore conducted an observational cohort study of 686 patients with newly diagnosed Rai stage 0 CLL to evaluate whether statin or NSAID use was related to their clinical outcome or influenced the efficacy of rituximab therapy. At diagnosis, 136 (20%) patients took statins and 230 (34%) scheduled daily aspirin, ibuprofen, or naproxen. No difference in time to treatment was observed based on statin or NSAID use. Among patients receiving a rituximab-containing first-line therapy, no difference in time to salvage treatment was observed based on statin use. Although previous studies suggested statins may improve event free survival among patients with follicular lymphoma, we find no impact of statins on time to initial therapy in this large study of patients with Rai stage 0 CLL. The in vitro observation that statins reduce rituximab efficacy does not appear to have clinical significance in CLL care.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Time to First Treatment and Survival Among Rai Stage 0 CLL Patients Based on Statin Use
Figure 2
Figure 2
Time to First Treatment and Survival Among Rai Stage 0 CLL Patients Based on NSAID Use
Figure 3
Figure 3
Time to Salvage Therapy Among Patients Receiving Rituximab Containing First-line Therapy Based on Statin Use At Time of First Treatment (p=0.60)
See this image and copyright information in PMC

References

    1. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. Jama. 2002;287:337–344. - PubMed
    1. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother. 2008;42:1208–1215. - PubMed
    1. Solomon D. NSAIDs: Overview of Adverse Effects. UpToDate. 2009
    1. Endo A. The discovery and development of HMG-CoA reductase inhibitors. Atheroscler. 1992;2004;5(Suppl):67–80. - PubMed
    1. Jakobisiak M, Golab J. Potential antitumor effects of statins (Review) Int J Oncol. 2003;23:1055–1069. - PubMed

Publication types

MeSH terms

Substances